Loading news...
Aster Capital Management DIFC Ltd purchased a new position in shares of ResMed Inc. (NYSE: RMD) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 2,252 shares of the medical equipment provider's stock, valued at approximately $616,000. Other institutional
Empirical Asset Management LLC acquired a new stake in ResMed Inc. (NYSE: RMD) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 3,066 shares of the medical equipment provider's stock, valued at approximately $839,000. Several other institutional investors have also made
ResMed (RMD) stock is currently at a fascinating juncture. It is trading at a low price, and if you decide to invest in it, you are wagering on a company that is demonstrating reasonable growth, maintaining solid cash flow and margin, has a low-debt capital structure, and is fairly valued.
Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. RL, EAT, FTI and RMD hold promise.
SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, is opening a new distribution center in Greenwood, Indiana. Scheduled to begin operations in 2027, the center will expand Resmed's U.S. presence and strengthen the company's distribution capacity to better serve patients and providers across North America.
Dana Investment Advisors Inc. reduced its stake in ResMed Inc. (NYSE: RMD) by 13.8% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 26,724 shares of the medical equipment provider's stock after selling 4,272 shares during the period. Dana
Apriem Advisors reduced its stake in shares of ResMed Inc. (NYSE: RMD) by 8.5% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 31,152 shares of the medical equipment provider's stock after selling 2,891 shares during the period.
Aberdeen Group plc decreased its holdings in shares of ResMed Inc. (NYSE: RMD) by 6.6% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 276,973 shares of the medical equipment provider's stock after selling 19,579 shares during the
Shares of ResMed Inc. (NYSE: RMD - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the fourteen brokerages that are currently covering the company, Marketbeat reports. Four analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to
Guru Stock PicksAl Gore has made the following transactions:Reduce in NTNX by 46.77%Sold out in MCHPAdd in MELI by 2.52%New position in CSLKen Fisher has made t
Stock News Futures edge up as jobs data and earnings mix: U.S. stock futures inched higher after January payrolls rose 130,000 with unemployment at 4.3%, compli
The GARP strategy helps investors gain exposure to stocks that have solid prospects and are trading at a discount. APH, GE, RMD and AMP are some such stocks.
Resmed shares rise after Q2 EPS and revenues beat expectations, with the gross and operating margins expanding sharply across core segments.
The Zacks Medical Products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. BSX, RMD, PAHC and BLFS reflect the favorable fundamentals.
Sleep-breathing device maker ResMed plans to take global a doctor education program aimed at promoting the screening of patients seeking Ozempic-style weight loss drugs for apnea, calling the GLP‑1 boom a lift, not a threat, to sales.
The Zacks Medical products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. BSX, RMD, PAHC and BLFS reflect the favorable fundamentals.
ResMed: Facing A Potentially Dream-Disrupting Dose - Strong Sell
On Thursday, ResMed Inc (NYSE: RMD) reported that second-quarter fiscal 2026 adjusted earnings of 2.81, beating the consensus of $2.72.
AlphaQuest LLC raised its position in ResMed Inc. (NYSE: RMD) by 1,038.0% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,363 shares of the medical equipment provider's stock after buying an additional 14,013 shares during the
ResMed (NYSE: RMD) executives highlighted revenue growth, margin expansion and continued investment in product development and demand-generation initiatives during the company's second quarter fiscal 2026 earnings call. Management also discussed progress in its software portfolio, the company's view of GLP-1 medications as a demand tailwind, and capital returns that were stepped up through an expanded share